Clinical Trial Update: To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients [Phase 1]

View source ↗

Summary

An update on a Phase 1 pharmacokinetics study of AZD1656 and its metabolite in patients with Type 2 Diabetes Mellitus. The trial status indicates completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• AZD1656

Snippet

Sponsor: AstraZeneca | Conditions: Glucose Lowering | Phase 1 | Status: COMPLETED